About this episode
Dr. Jaime Imitola discusses the landscape of stem cell therapies in multiple sclerosis and the importance of patient education.
Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments, investigational approaches, and unproven interventions marketed through stem cell tourism. Hear more as Dr. Jaime Imitola discusses the current landscape of stem cell therapies in MS, the risks associated with unregulated treatments, and the importance of patient education and evidence-based guidance. Dr. Imitola is the Vice Chair for Research of the Department of Neurology and the Director of the Division of Multiple Sclerosis and Translational Neuroimmunology at UConn Health. He also spoke about this topic at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.
People in this episode
Guests: Jaime Imitola, MD, Jaime Imitola
Topics covered
- stem cell therapy
- multiple sclerosis
- patient education
- evidence-based guidance
- unproven interventions
Keywords
- stem cell therapy
- multiple sclerosis
- patient education
- unregulated treatments
- evidence-based guidance
Mentioned in this episode
Organizations: UConn Health
Places: multiple sclerosis
More episodes of NeuroFrontiers
- Cognitive Screening in MS: Practical Strategies and Modern Approaches · May 28, 2026 · 4 min
- Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols · May 14, 2026 · 14 min
- Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role · May 14, 2026 · 15 min
- Understanding Variability in Myasthenia Gravis · May 1, 2026 · 4 min
- Examining the Global Genetic Prevalence of TK2d · April 30, 2026 · 14 min
- Applying the 2024 McDonald Criteria: Real-World Impacts on MS Diagnosis · March 30, 2026 · 3 min
Explore listener stats, chart rankings, contacts and more on the NeuroFrontiers podcast page.